In:
International Journal of Cancer, Wiley, Vol. 145, No. 12 ( 2019-12-15), p. 3276-3284
Abstract:
What's new? The CSF1‐COL6A3 fusion gene has been detected in a third of tenosynovial giant cell tumor (TSGCT) cases, but additional signaling pathways or mutations may be involved. Here, RNA sequencing reveals several fusion transcripts involving CSF1 , including novel CSF1‐VCAM1 , CSF1‐FN1 and CSF1‐CDH1 fusions, in 72% of TSGCT cases. All CSF1 fusion transcripts result in the deletion of CSF1 exon 9, a negative regulator of CSF1 expression. Moreover, novel CBL mutations are found in 35% of tumors, with or without the presence of CSF1 fusions. The data may contribute to the development of new targeted therapies and reveal the etiology of TSGCT.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink